Every patient in a small clinical trial at Memorial Sloan Kettering Cancer Center saw their rectal cancer vanish after ...

Patients with mismatch repair deficient gastric cancer demonstrated better median overall survival when skipping perioperative chemotherapy, according to a preprint study. Median overall survival is ...

The ATOMIC Trial shows how adding immunotherapy to chemotherapy may reduce recurrence risk and improve outcomes in stage III ...

Memorial Sloan Kettering Cancer Center reported that every patient in a trial for mismatch repair-deficient locally advanced ...

Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data Patients with stage I-III colon cancer treated with upfront ...

Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image–Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study The College of American ...

Please provide your email address to receive an email when new articles are posted on . Mismatch repair (MMR) screening showed MMR deficiency in one-third of sebaceous carcinoma (SC) cases. Rates of ...

The US Food and Drug Administration has approved a DNA mismatch repair (MMR) companion test to identify patients suitable for treatment with Merck's pembrolizumab (Keytruda). The Ventana MMR RxDx ...

DNA is well known as the blueprint of life, necessary for an organism to facilitate living processes. DNA can be damaged by various factors such as radical metabolites, radiation, and some toxic ...

Please provide your email address to receive an email when new articles are posted on . Results showed a DFS benefit with the addition of pembrolizumab to chemotherapy for patients with mismatch ...